In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia, discussed results of a post hoc analysis of the CANDELA study. Dr Fein described the primary and secondary endpoints and the potential clinical impact of the findings.
Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the…
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions.…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
